![Krumholz Harlan Aih24](https://aspenideasfestival.imgix.net/a9f3f022-cdfa-4199-a90a-7b6a808f189b/Krumholz_Harlan_AIH24.jpeg?auto=compress%2Cformat&fit=min&fm=jpg&h=290&q=80&rect=0%2C28%2C3024%2C3029&w=290)
Harlan Krumholz
Professor of Medicine and Founder and Director, Center for Outcomes Research and Evaluation, Yale University and Yale New Haven Hospital
Harlan Krumholz is a Harold H. Hines, Jr., Professor of Medicine, founder and director of the Yale New Haven Hospital Center for Outcomes Research and Evaluation, and incoming editor-in-chief of JACC. A cardiologist, Krumholz is a pioneering outcomes researcher and highly cited medical researcher, with over 1600 scientific articles. He has developed transformative strategies to measure and improve health care quality, patient outcomes, and health equity; promote open science and transform research processes; support patient engagement and empowerment; and apply digital technologies and computational approaches to accelerate clinical care and research progress. He is a member of the National Academy of Medicine, distinguished scientist of the American Heart Association, and founding governor of the Patient-Centered Outcomes Research Institute. Krumholz co-founded the Yale University Open Data Access Project, medRxiv, and data technology companies Hugo Health, Refactor Health, and Ensight-AI.
Previously
![GLP-1 Agonists: Wonder Drugs of the 21st Century?](https://aspenideasfestival.imgix.net/8c839279-ecc7-4717-8a12-38a8a9f64bcd/53812131104_87f7a9dc2b_o.jpg?auto=compress%2Cformat&fit=min&fm=jpg&h=225&q=80&rect=0%2C824%2C5504%2C3092&w=400)
The first drug in a class known as GLP-1 agonists was approved in 2005 to treat diabetes. GLP-1 drugs subsequently proved their mettle to treat obesity and prevent major cardi...